HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating for Prelude Therapeutics (NASDAQ:PRLD) and maintained a $5 price target.
September 10, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Prelude Therapeutics, maintaining a $5 price target. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $5 price target by HC Wainwright & Co. indicates that the analyst does not foresee significant changes in the stock's performance in the short term. This suggests stability in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100